Keywords: raloxifene, efficacy, breast, cancer, eli, lilly, selective
Raloxifene Efficacy In Breast Cancer
Article | 21 May 1998
Eli Lilly's selective estrogen receptor modulator Evista (raloxifene),approved for the prevention of postmenopausal osteoporosis, has been shown to reduce ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- AstraZeneca plans to move three cancer drug candidates into Ph III
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Merck Serono Ph III trial of L-BLP25 fails endpoint in NSCLC
